Skip to content
 +33 (0)5 35 54 19 36       contact@matwin.fr
FacebookXYouTubeLinkedIn
Matwin Logo Matwin Logo Matwin Logo
  • HOME
  • WHO ARE WE ?
    • MATWIN’s platform
    • Our partners
    • MATWIN International Board
    • The team
  • OUR ACTIONS
    • Accelerating programme
    • Tailor made service offers
    • MEET2WIN
    • OUI INVESTMENT
    • OncoSTART
  • CALLS FOR APPLICATION
    • MATWIN’s Call for applications
    • MATWIN projects’ portfolio
    • Other calls for application
  • NEWS
    • News
    • Agenda
    • Press
  • CONTACT
  • Français
  • English
  • HOME
  • WHO ARE WE ?
    • MATWIN’s platform
    • Our partners
    • MATWIN International Board
    • The team
  • OUR ACTIONS
    • Accelerating programme
    • Tailor made service offers
    • MEET2WIN
    • OUI INVESTMENT
    • OncoSTART
  • CALLS FOR APPLICATION
    • MATWIN’s Call for applications
    • MATWIN projects’ portfolio
    • Other calls for application
  • NEWS
    • News
    • Agenda
    • Press
  • CONTACT
  • Français
  • English
  • HOME
  • WHO ARE WE ?
    • MATWIN’s platform
    • Our partners
    • MATWIN International Board
    • The team
  • OUR ACTIONS
    • Accelerating programme
    • Tailor made service offers
    • MEET2WIN
    • OUI INVESTMENT
    • OncoSTART
  • CALLS FOR APPLICATION
    • MATWIN’s Call for applications
    • MATWIN projects’ portfolio
    • Other calls for application
  • NEWS
    • News
    • Agenda
    • Press
  • CONTACT
  • Français
  • English

MATWIN ANNUAL REPORT 2019

stephanie.dhont2020-05-06T09:56:59+02:00

Partagez cette histoire, choisissez votre plate-forme !

FacebookXRedditLinkedInTumblrPinterest

Related Posts

Apmonia Therapeutics laureate from EIC accelerator program
Apmonia Therapeutics laureate from EIC accelerator program

Apmonia Therapeutics laureate from EIC accelerator program

HEPHAISTOS secures €10.3 M to reach the clinical stage
HEPHAISTOS secures €10.3 M to reach the clinical stage

HEPHAISTOS secures €10.3 M to reach the clinical stage

PDC*line Pharma completes enrolment of four cohorts of patients in PDC-LUNG-101 phase I/II clinical trial
PDC*line Pharma completes enrolment of four cohorts of patients in PDC-LUNG-101 phase I/II clinical trial

PDC*line Pharma completes enrolment of four cohorts of patients in PDC-LUNG-101 phase I/II clinical trial

Newsletter MATWIN June 2023
Newsletter MATWIN June 2023

Newsletter MATWIN June 2023

MATWIN – PSCC partnership – Interview Benjamin Garel
MATWIN – PSCC partnership – Interview Benjamin Garel

MATWIN – PSCC partnership – Interview Benjamin Garel

Categories

  • Call for application (41)
  • Diary (11)
  • News (36)
  • Non classé (3)
  • Press (19)

Follow us

MATWIN Copyright 2017 | All Rights Reserved | Powered by Argonautt | Imprint
FacebookXYouTubeLinkedIn
Page load link
Pour mieux vous connaître et améliorer notre site, nous utilisons des cookies. En continuant votre visite, vous acceptez notre politique de cookie.ContinueNoPLUS
Go to Top